Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study

• Published in: PloS one 2019-02, Vol.14 (2), p.e0212989-e0212989
• Main Authors: Motoya, Satoshi, Watanabe, Kenji, Ogata, Haruhiko, Kanai, Takanori, Matsui, Toshiyuki, Suzuki, Yasuo, Shikamura, Mitsuhiro, Sugiura, Kenkichi, Oda, Kazunori, Hori, Tetsuharu, Araki, Takahiro, Watanabe, Mamoru, Hibi, Toshifumi
• Format: Article
• Language: English
• Subjects: Annual reports; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Biology and Life Sciences; Clinical trials; Colitis; Colitis, Ulcerative - drug therapy; Colon; Complications and side effects; Crohn's disease; Crohns disease; Dosage and administration; Double-Blind Method; Double-blind studies; Drug therapy; Enrollments; Gastroenterology; Gastrointestinal Agents - administration & dosage; Gastrointestinal Agents - adverse effects; Gastrointestinal Agents - therapeutic use; Hepatology; Hospitals; Humans; Induction therapy; Inflammatory bowel disease; Internal medicine; Japan; Labels; Maintenance; Medical research; Medicine; Medicine and Health Sciences; Monoclonal antibodies; Patient outcomes; Patients; People and Places; Pharmaceutical industry; Placebos; Population; Randomization; Remission; Research and analysis methods; Safety; Statistical analysis; Studies; Therapy; Tumor necrosis factor-TNF; Ulcerative colitis; Vedolizumab
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0212989

Vedolizumab safety and efficacy have been established in many populations all over the world, but have never been studied in Japan. We report results from a Phase 3, randomized, double-blind, placebo-controlled study of vedolizumab in Japanese patients with active ulcerative colitis (UC). Patients with moderate-to-severe UC were enrolled into Cohort 1 (double-blinded) or Cohort 2 (open-label) in the induction phase. Cohort 1 was randomized 2:1 to receive 300 mg vedolizumab or placebo, while Cohort 2 received vedolizumab 300 mg only, at Weeks 0, 2, and 6. Patients from Cohorts 1 and 2 showing a clinical response to vedolizumab at Week 10 were randomized 1:1 to receive vedolizumab or placebo (double-blinded) at Week 14 and then every 8 weeks up to Week 54 as the maintenance phase. The primary endpoint was clinical response at Week 10, for the induction phase, and clinical remission at Week 60, for the maintenance phase. A total of 292 patients were enrolled into the induction phase (246 in Cohort 1, 46 in Cohort 2); 83 patients achieved response to vedolizumab and were subsequently enrolled into the maintenance phase. Clinical response rates at Week 10 were 39.6% (65/164) and 32.9% (27/82) in the vedolizumab and placebo groups in Cohort 1, respectively (adjusted odds ratio [AOR] = 1.37, 95% CI 0.779-2.399; p = 0.2722). In the maintenance phase, clinical remission rate at Week 60 was significantly higher in the vedolizumab group, at 56.1% (23/41), versus 31.0% (13/42) for placebo (AOR = 2.88, 95% CI 1.168-7.108; p = 0.0210). Most adverse events were mild to moderate in intensity, and no deaths occurred during the study period. Vedolizumab showed numerically greater efficacy compared with placebo as induction therapy, but the difference was not statistically significant. Vedolizumab was significantly superior to placebo as maintenance therapy in Japanese patients with UC. Vedolizumab has favourable safety and tolerability in these patients. ClinicalTrials.gov: NCT02039505.